
- Lyra Medical was founded in 2011 and is located in Israel. All R&D and manufacturing is made in Israel
- Concept behind developing the SRS implant for POP procedures was that most complications from trans-vaginal mesh procedure do not come from the use of mesh but from the need to anchor it in pelvic compartment. See link attached:
Australian Study– https://www.linkedin.com/posts/lyra-medical_descriptive-study-of-anchoring-failure-in-activity-6720948514861420544-9Y4U
- Company carries CE Mark, Israeli MOH cert. and started regulatory process in Asian countries
- SRS is marketed in Germany, Switzerland, Austria, Italy, Israel and more across EU.
- Company has published clinical data for SRS showing substantial superiority to any other solution on the market. Please see link attached:
https://www.linkedin.com/posts/lyra-medical_lyramedical-srs-pelvic-activity-6727497495775084544-1Rcs
- Use of the SRS implant provides the following benefits:
- Higher short and long term safety rate than any implant of market
- Higher long term efficacy than other implants and Native Tissue procedure
- Reducing procedure time by about 70-80% compared to mesh procedures
- Shorter hospitalization time (based on feedback from German surgeons- non-official)
Short testimonial from a KOL in Italy (includes audio): https://www.linkedin.com/posts/lyra-medical_srs-activity-6739098228869869568-o9vn
For more information, you can visit www.lyramedical.com or contact jeremy.ungar@israeltrade.gov.il